Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BIA 9-1067 on Levodopa Pharmacokinetics in Parkinson's Disease
NCT01568034Phase 2Completed
- Sponsor
- BIAL
- Start
- Apr 2009
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of opicapone in Parkinson's disease (PD) (4 arms), sponsored by BIAL. Primary endpoints: Maximum Plasma Concentration at Day 3 and Time to Maximum Plasma Concentration at Day 3. Started Apr 2009; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01568034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01568034.